Skip to main content
SpringerLink
Log in
Book cover

Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery pp 55–66Cite as

Early-Onset Pro-inflammatory Cytokines

  • Conference paper

  • 1170 Accesses

Part of the book series: Update in Intensive Care and Emergency Medicine ((UICMSOFT,volume 44))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dinarello CA (2000) Proinflammatory cytokines. Chest 118:503–508

    Article  PubMed  CAS  Google Scholar 

  2. Calandra T, Bochud PY, Heumann D (2002) Cytokines in septic shock. Curr Clin Top Infect Dis 22:1–23

    PubMed  Google Scholar 

  3. Hehlgans T, Pfeffer K (2005) The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115:1–20

    Article  PubMed  CAS  Google Scholar 

  4. Spinas GA, Keller U, Brockhaus M (1992) Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 90:533–536

    PubMed  CAS  Google Scholar 

  5. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A 89:4845–4849

    Article  PubMed  Google Scholar 

  6. Aderka D, Engelmann H, Maor YBC, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323–329

    Article  PubMed  CAS  Google Scholar 

  7. Evans TJ, Moyes D, Carpenter A, et al (1994) Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 180:2173–2179

    Article  PubMed  CAS  Google Scholar 

  8. Mohler KM, Torrance DS, Smith CA, et al (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548–1561

    PubMed  CAS  Google Scholar 

  9. Moller B, Ellermann-Eriksen S, Storgaard M, Obel N, Bendtzen K, Petersen CM (1996) Soluble tumor necrosis factor (TNF) receptors conserve TNF bioactivity in meningitis patient spinal fluid. J Infect Dis 174:557–563

    PubMed  CAS  Google Scholar 

  10. Tracey KJ, Beutler B, Lowry SF, et al (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470–474

    Article  PubMed  CAS  Google Scholar 

  11. Waage A, Halstensen A, Espevik T (1987) Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1:355–357

    Article  PubMed  CAS  Google Scholar 

  12. Girardin E, Grau G, Dayer J, Roux-Lombard P, Lambert PH (1988) Tumor necrosis factor and interleukin-1 in serum of children with severe infectious purpura. N Engl J Med 319:397–400

    Article  PubMed  CAS  Google Scholar 

  13. Calandra T, Baumgartner JD, Grau GE, et al (1990) Prognostic values of tumor necrosis factor/ cachectin, interleukin-1, alpha-interferon and gamma-interferon in the serumof patients with septic shock. J Infect Dis 161:982–987

    PubMed  CAS  Google Scholar 

  14. Panacek EA, Marshall JC, Albertson TE, et al (2004) Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab’)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 32:2173–2182

    PubMed  CAS  Google Scholar 

  15. Fisher CJ, Agosti JM, Opal SM, et al (1996) Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 334:1697–1702

    Article  PubMed  CAS  Google Scholar 

  16. Abraham E, Glauser MP, Butler T, et al (1997) p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. JAMA 277:1531–1538

    Article  PubMed  CAS  Google Scholar 

  17. Abraham E, Laterre PF, Garbino J, et al (2001) Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebocontrolled, multicenter phase III trial with 1,342 patients. Crit Care Med 29:503–510

    Article  PubMed  CAS  Google Scholar 

  18. Dinarello CA (1998) Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Intern Rev Immunol 16:457–499

    CAS  Google Scholar 

  19. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA (1988) Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 81:1162–1172

    PubMed  CAS  Google Scholar 

  20. Waage A, Espevik T (1988) Interleukin-1 potentiates the lethal effect of TNF-alpha/cachectin in mice. J Exp Med 167:1987–1992

    Article  PubMed  CAS  Google Scholar 

  21. Fantuzzi G, Zheng H, Faggioni R, et al (1996) Effect of endotoxin in IL-1β-deficient mice. J Immunol 157:291–296

    PubMed  CAS  Google Scholar 

  22. Ohlsson K, Björk P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550–552

    Article  PubMed  CAS  Google Scholar 

  23. Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA (1991) A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 173:1029–1032

    Article  PubMed  CAS  Google Scholar 

  24. Fischer E, Marano MA, Van Zee KJ, et al (1992) Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 89:1551–1557

    Article  PubMed  CAS  Google Scholar 

  25. Fisher CJ, Jr., Slotman GJ, Opal SM, et al (1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22:12–21

    PubMed  Google Scholar 

  26. Fisher CJ, Dhainaut JF, Opal SM, et al (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 271:1836–1843

    Article  PubMed  Google Scholar 

  27. Opal SM, Fisher CJ, Dhainaut JF, et al (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 25:1115–1124

    Article  PubMed  CAS  Google Scholar 

  28. Jones SA (2005) Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 175:3463–3468

    PubMed  CAS  Google Scholar 

  29. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP, and the Swiss-Dutch J5 study group (1991) High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 91:23–29

    Article  PubMed  CAS  Google Scholar 

  30. Oberholzer A, Souza SM, Tschoeke SK, et al (2005) Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock 23:488–493

    PubMed  CAS  Google Scholar 

  31. Reinhart K, Menges T, Gardlund B, et al (2001) Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 29:765–769

    Article  PubMed  CAS  Google Scholar 

  32. Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75:163–189

    Article  PubMed  CAS  Google Scholar 

  33. Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133–146

    Article  PubMed  CAS  Google Scholar 

  34. Akira S (2000) The role of IL-18 in innate imunity. Curr Op Immunol 12:59–63

    Article  CAS  Google Scholar 

  35. Lainee P, Efron P, Tschoeke SK, et al (2005) Delayed neutralization of interferon-gamma prevents lethality in primate Gram-negative bacteremic shock. Crit Care Med 33:797–805

    Article  PubMed  CAS  Google Scholar 

  36. Docke WD, Randow F, Syrbe U, et al (1997) Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3:678–681

    Article  PubMed  CAS  Google Scholar 

  37. Kox WJ, Bone RC, Krausch D, et al (1997) Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med 157:389–393

    Article  PubMed  CAS  Google Scholar 

  38. Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791–800

    Article  PubMed  CAS  Google Scholar 

  39. Bloom BR, Bennett B (1966) Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153:80–82

    Article  PubMed  CAS  Google Scholar 

  40. David J (1966) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56:72–77

    Article  PubMed  CAS  Google Scholar 

  41. Bacher M, Meinhardt A, Lan HY, et al (1997) Migration inhibitory factor expression in experimentally induced endotoxemia. Amer J Pathol 150:235–246

    CAS  Google Scholar 

  42. Bernhagen J, Calandra T, Mitchell RA, et al (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365:756–759

    Article  PubMed  CAS  Google Scholar 

  43. Calandra T, Bernhagen J, Metz CN, et al (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377:68–71

    Article  PubMed  CAS  Google Scholar 

  44. Calandra T, Bernhagen J, Mitchell RA, Bucala R (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179:1895–1902

    Article  PubMed  CAS  Google Scholar 

  45. Roger T, Chanson AL, Knaup-Reymond M, Calandra T (2005) Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol 35:3405–3413

    Article  PubMed  CAS  Google Scholar 

  46. Calandra T, Echtenacher B, Roy DL, et al (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6:164–170

    Article  PubMed  CAS  Google Scholar 

  47. Marshall JC (2003) Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2:391–405

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Diseases Service Department of Medicine, Centre Hospitalier Universitaire Vaudois, 1011, Lausanne, Switzerland

    C. Kaech & T. Calandra

Authors
  1. C. Kaech
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Calandra
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Health Sciences Center, Division Pulmonary & Critical Care Medicine, University of Colorado, E. Ninth Avenue 4200, 80262, Denver, CO, USA

    Edward Abraham MD

  2. Bloomsbury Institute of Intensive Care, Division Medicine, University College Hospital, Gower Street, WC1E 6BT, London, UK

    Mervyn Singer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Kaech, C., Calandra, T. (2007). Early-Onset Pro-inflammatory Cytokines. In: Abraham, E., Singer, M. (eds) Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery. Update in Intensive Care and Emergency Medicine, vol 44. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-30328-6_4

Download citation

  • DOI: https://doi.org/10.1007/3-540-30328-6_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-30157-8

  • Online ISBN: 978-3-540-30328-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation